Towards Skin Point-of Care Devices For Personalized Skin Treatment Based On Non-invasive Biomarker Measurements Directly From The Skin Surface | 54458
Journal of Infectious Diseases & Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Diagnosis of chronic skin inflammation is largely performed by visual assessment, for instance by judging the shape, pattern,
position, thickness, redness and scaling of skin lesions on the body. These phenotypic characteristics are typically end-products
of the underlying biological processes responsible for disease. Despite the unquestionable value of visual assessment for treatment
decisions and patient monitoring, more detailed analyses methods are needed for answering the unmet medical need for offering
personalized medicine to patients, e.g., methods that can be used for selection as well as fine-tuning of treatment. Proteins that
play a crucial role in skin inflammation, such as cytokines and chemokines, form the molecular root of inflammation and thus
have tremendous value for catering personalized medicine in the form of biomarkers. Skin biomarker measurements are typically
performed on skin material obtained through invasive procedures and analyses are typically costly and elaborate. FibroTx TAP
and SELF are novel molecular diagnostic platform technologies for biomarker measurements directly from skin. These platform
technologies are currently being tested in clinical studies for the development of skin diagnostic tools that can objectively assess the
disease activity status of skin lesions. The aim of the studies is to develop practical point-of-care devices that can markedly improve
skin treatment, which is cost-efficient and does not require the need for extensive clinical laboratory expertise.
Pieter Spee has received his PhD in Immunology from the Netherlands Cancer Institute, University of Leiden. While at Novo Nordisk, he made significant contributions to Lirilumab and Monalizumab, both currently in phase II clinical development by BMS and AstraZeneca in collaboration with Innate Pharma, respectively. As a Director and Scientific Director, he was heading up preclinical translational research at Novo Nordisk. In 2012, he founded PS Pharmaconsult, offering expert advice on drug and medical device development through a unique 360 degrees patient centric approach. Currently, he functions as a Chief Technology Officer at FibroTx LLC, developing two highly innovative skin diagnostic devices, TAP and SELF, allowing personalized medicine in skin care and clinical dermatology.